Obesity

Adults who are underweight, overweight, or obese face higher medical expenditures, varying by age, sex, and care setting.

Explore the evolving GLP-1 landscape with insights from industry experts, shaping future health strategies and plan designs for employers.

Aleata Postell discusses CenterWell Pharmacy's partnership with Eli Lilly to dispense FDA-approved obesity management drugs.

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.

The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, and ketamine-assisted therapy.

Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, patient-centered care model.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Explore the evolving landscape of biologics in metabolic syndrome treatment, highlighting GLP-1 analogs and PCSK9 inhibitors for improved patient outcomes.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

Discontinuing GLP-1 use before or early in pregnancy raises gestational weight gain, birth weight percentile, and the risk of pregnancy complications.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Semaglutide and tirzepatide led to the most weight loss across 22 trials, while liraglutide remains a cost-effective alternative as its patent expires.

Consistent across age, sex, and race, BMI closely mirrored body fat–based obesity in nearly all US youth with BMI-defined obesity (BDO).

The founder and President of Phesi addresses the need for streamlining clinical trial data as GLP-1 RA therapies are being used to treat multiple diseases.

David Rometo, MD, reflects on the sustainability of incremental weight loss programs and aggressive diets.

Social determinants of health disproportionately impact patients' ability to maintain and achieve their weight loss goals.

Research highlights disparities in anti-obesity medication use and metabolic and bariatric surgery.

The European Association for the Study of Obesity now recommends the 2 treatments for obesity and most associated complications.

Here are 5 reasons why bariatric surgery may be better for weight loss than GLP-1 receptor agonists

Bariatric surgery is more efficient at increasing weight loss and more cost-effective than GLP-1 RAs.

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

This commentary calls for health care systems to deliver equitable care for people living with obesity by addressing weight bias and updating standards in obesity care.

Bariatric surgery reduces the likelihood of obesity-related comorbidities compared with nonsurgical weight loss interventions.